DCGI Approves DRDO-Developed Technology Behind Critical Drug for Radiological & Nuclear Emergencies

New Delhi: The manufacturing and marketing licenses for the commercial use of Prussian blue insoluble formulations have been granted to Scott-Edil Pharmacia Limited, Himachal Pradesh and Skanttr Lifescience, Gujarat by the Drugs Controller General of India.

It is one of the critical medicines listed by the World Health Organisation for radiological and nuclear emergencies. Defence Ministry said the drug will be available under the trade name of Pru-DecorpTM and PruDecorp-MG.

The formulations are used for the decontamination of Cesium and Thallium and their Active Pharmaceutical Ingredients. The drug has been developed by the industry based on the technology of the Institute of Nuclear Medicine and Allied Sciences, Delhi, a laboratory of the Defence Research and Development Organisation (DRDO).

Secretary, Department of Defence Research and Development and Chairman DRDO Dr Samir V Kamat have congratulated the Organisation as well as the industry on this achievement.

He stated that the development of these drug formulations under the Technology Development Fund project is a successful endeavour of the DRDO for promoting the industry to achieve the vision of Aatmanirbhar Bharat.